{"entity":{"id":"nct06979908","kind":"trial","name":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C","aka":[],"tldr":"A phase 2 trial of fruquintinib, sintilimab and tucidinostat (chidamide) in colorectal cancer, run by The First Hospital of Jilin University, now recruiting.","summary":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06979908 by The First Hospital of Jilin University, with a registry enrolment figure of 46 participants, started 2025-01-22 and due to reach its primary completion in 2026-07-22. Interventions recorded: Fruquintinib+Sintilimab+Chidamide. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: PFS. Colorectal eligibility wording from the registry: \"* Histologically confirmed colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06979908","url":"https://clinicaltrials.gov/study/NCT06979908"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["fruquintinib","sintilimab","tucidinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06979908","phase":"2","setting":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer","sponsor":"The First Hospital of Jilin University","participation":[{"nct":"NCT06979908","source":"https://clinicaltrials.gov/study/NCT06979908","fetchedAt":"2026-10-07T16:55:20.203Z","studySha256":"2ef9bdc4d231e4fb5db5e2c09aa99a2b2a7eb8d005a58bcdb8a4cd23e52a1f5a","overallStatus":"RECRUITING","lastUpdatePosted":"2025-05-20","leadSponsor":"The First Hospital of Jilin University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":46,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-01-22","startedType":"actual","enrolled":46,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06979908/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"},{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}